Pages that link to "Q71747729"

The following pages link to Ronit Simantov (Q71747729):

Displaying 25 items.

• Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1 (Q24290677) (← links)
• CD36: a critical anti-angiogenic receptor (Q28205179) (← links)
• Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer (Q28275492) (← links)
• Sorafenib in advanced clear-cell renal-cell carcinoma (Q28282767) (← links)
• The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein (Q28594691) (← links)
• Activation of cultured vascular endothelial cells by antiphospholipid antibodies. (Q33488617) (← links)
• Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. (Q33502592) (← links)
• Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. (Q34090594) (← links)
• Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. (Q35939172) (← links)
• Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. (Q36051199) (← links)
• Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma (Q36062302) (← links)
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. (Q36610990) (← links)
• Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. (Q40238484) (← links)
• GPNMB expression in uveal melanoma: a potential for targeted therapy. (Q42655793) (← links)
• Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors (Q42681386) (← links)
• Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. (Q50448767) (← links)
• A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. (Q52873936) (← links)
• Antiphospholipid antibodies activate vascular endothelial cells (Q71747732) (← links)
• Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies (Q71843089) (← links)
• Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis (Q73867179) (← links)
• Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in Sjögren's syndrome (Q75288444) (← links)
• Thrombosis and malignancy: pathogenesis and prevention (Q77801658) (← links)
• Genetic background determines the extent of atherosclerosis in ApoE-deficient mice (Q78122014) (← links)
• Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer (Q80249413) (← links)
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma (Q83195713) (← links)